The ESMO Asia 2025 (ESMOAsia25) is taking place from December 5-7, 2025, in Singapore
The congress serves as a vital platform to advance cancer care through the latest scientific discoveries, innovative therapies, and evolving clinical practices. Whether you’re a clinician, researcher, or healthcare provider, this gathering offers a front-row seat to the future of oncology.
David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared some insights from the event:
“The joys of networking at ESMO Asia!”
Excellent discussion by Noemie
“Excellent discussion by Noemie on 3 major abstracts during the lung oral session in Singapore today ESMOASIA25: ADCs, PRMT5i (MTAP loss), and CIK therapy… impressive!”
The battle of HER2 inhibitors in lung cancer
“The battle of HER2 inhibitors in lung cancer ESMOASIA25 …Two excellent presentations from the Asian cohorts. Awaiting access in Europe!”
A new player in targeting EGFR-PACC mutations
“A new player in targeting EGFR-PACC mutations, efficacy reported… results are still preliminary and require confirmation in a larger cohort, as well as more information on intra-cerebral efficacy. ”
EGFR session chaired by Jordi Remon and Pr Myung-Ju Ahn
“EGFR session chaired by Jordi Remon and Pr Myung-Ju Ahn… a great opportunity to learn even more about the advances for our patients and the diversity of EGFR alterations requiring specific therapeutic choices!”
Excellent overview by Jordi Remon
“Excellent overview by Jordi Remon on the latest developments in uncommon EGFR mutations… very interesting efficacy of 3rd generation EGFR TKIs!”
Confirmation of the efficacy of Elironrasib
“Confirmation of the efficacy of Elironrasib in pretreated KRAS G12C NSCLC patients, but without prior KRAS inhibitor therapy.”
Skin toxicities in Asian patients
“A significant % of grade 2-3 skin toxicities (not even counting G 1, which can impact pts’ quality of life) persists in Asian pts, despite maximized application of cream over the entire body… and this only within 3 mo, with no data available on cumulative toxicities.”
“Excellent NEOLA Phase 2 trial, demonstrating the safety of induction with osimertinib prior to CRT in EGFRm patients with unresectable Stage III. Great ORR as expected and an interesting reduction of the radiotherapy field. Awaiting EFS and OS data…”
You can find more posts from ESMO Asia 2025 on OncoDaily.